Labcyte is best known for its EchoÂ®Â acoustic droplet ejection technology, which uses sound waves to transfer tiny amounts of liquid with unequalled speed and accuracy. This technologyâthe centerpiece of Labcyte’s Echo Liquid Handlersâenables walkaway convenience and integration capabilities. Labcyte technology enables faster and more cost-effective laboratory workflows in applications such as drug discovery and genomics.
“Labcyte’s unique product portfolio complements our existing liquid handling and laboratory automation business. It provides new opportunities to develop and enhance time-saving solutions for customer workflows,” saidÂ Jonathan Pratt, President, Beckman Coulter Life Sciences. “Labcyte and Beckman Coulter Life Sciences share a common vision of advancing science through discovery, enabling the faster discovery and development of life-changing advances in medicine. Together we will make a powerful team, and an invaluable resource for current and future customers around the world.”
“It has been an exciting journeyâfrom developing acoustic liquid-dispensing technology in a garage to establishing a global presence, and now to be joining forces with a life sciences technology leader,” saidÂ Richard Ellson, CTO and a Founder of Labcyte.Â “AcousticÂ liquid handling is quickly becoming the backbone for high-throughput, automated workflows, and we look forward to accelerating growth and innovation as part of the Beckman Coulter Life Sciences team.”
Labcyte will transition into Beckman Coulter Life Sciences under the larger Danaher Life Sciences platform of companies, which generates approximatelyÂ $6.5 billionÂ in annual revenue.